Published in:
Open Access
01-12-2012 | Research article
Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study
Authors:
Galo Peralta, María Lamelo, Patricia Álvarez-García, María Velasco, Alberto Delgado, Juan Pablo Horcajada, María Montero, María Pía Roiz, Maria Carmen Fariñas, Juan Alonso, Luis Martínez Martínez, Alfonso Gutiérrez-Macías, Jose Angel Alava, Azucena Rodríguez, Ana Fleites, Vicente Navarro, Elia Sirvent, Jose Antonio Capdevila
Published in:
BMC Infectious Diseases
|
Issue 1/2012
Login to get access
Abstract
Background
The objective of this study is to analyze the factors that are associated with the adequacy of empirical antibiotic therapy and its impact in mortality in a large cohort of patients with extended-spectrum β-lactamase (ESBL) - producing Escherichia coli and Klebsiella spp. bacteremia.
Methods
Cases of ESBL producing Enterobacteriaceae (ESBL-E) bacteremia collected from 2003 through 2008 in 19 hospitals in Spain. Statistical analysis was performed using multivariate logistic regression.
Results
We analyzed 387 cases ESBL-E bloodstream infections. The main sources of bacteremia were urinary tract (55.3%), biliary tract (12.7%), intra-abdominal (8.8%) and unknown origin (9.6%). Among all the 387 episodes, E. coli was isolated from blood cultures in 343 and in 45.71% the ESBL-E was multidrug resistant. Empirical antibiotic treatment was adequate in 48.8% of the cases and the in hospital mortality was 20.9%. In a multivariate analysis adequacy was a risk factor for death [adjusted OR (95% CI): 0.39 (0.31-0.97); P = 0.04], but not in patients without severe sepsis or shock. The class of antibiotic used empirically was not associated with prognosis in adequately treated patients.
Conclusion
ESBL-E bacteremia has a relatively high mortality that is partly related with a low adequacy of empirical antibiotic treatment. In selected subgroups the relevance of the adequacy of empirical therapy is limited.